Advertisement

Search Results

Advertisement



Your search for The ,The matches 30073 pages

Showing 1 - 50


Oncologists Look for Strong Health-Care Priorities in the State of the Union Address

In anticipation of President Joseph R. Biden’s State of the Union Address tonight, ASCO is urging the president to keep cancer care and research as top national priorities. Oncologists have seen how clinical research has improved prevention, detection, and treatment for millions of Americans and...

hematologic malignancies
symptom management

Axatilimab for Refractory Chronic Graft-vs-Host Disease

In a phase I/II study reported in the Journal of Clinical Oncology, Carrie L. Kitko, MD, and colleagues found that axatilimab, an anti–colony-stimulating factor 1 receptor (CSF-1R) antibody, produced high response rates in patients who had undergone allogeneic hematopoietic cell transplantation and ...

breast cancer

10-Year Outcomes With Adjuvant APBI Using Multicatheter Brachytherapy vs WBI After Breast-Conserving Surgery for Early Breast Cancer

As reported in The Lancet Oncology by Vratislav Strnad, MD, PhD, and colleagues, 10-year outcomes in a phase III GEC-ESTRO (Groupe Européen de Curiethérapie and European Society for Radiotherapy and Oncology) trial have shown no significant difference in ipsilateral breast cancer recurrence with...

hepatobiliary cancer

Expert Point of View: Imane H. El Dika, MD

The sessions’ invited discussant, Imane H. El Dika, MD, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center, New York, said the results of the two trials in advanced biliary tract cancer were clear, and did not change the current standard of care of durvalu­mab combined with...

hepatobiliary cancer

What Can Be Learned From Negative Findings of Two Trials in Biliary Tract Cancer

Biliary tract cancer is particularly difficult to treat, with a median overall survival of about 1 year with standard-of-care gemcitabine-based regimens. Advanced biliary tract cancer is an area of significant unmet need because of its aggressive nature, limited treatment options, and poor...

lung cancer
neuroendocrine tumors

SBRT for Patients With Primary Lung Neuroendocrine Tumors

Researchers have found that stereotactic body radiotherapy (SBRT) may be an effective treatment for patients with early-stage lung neuroendocrine tumors, according to a new study published by Oliver et al in the International Journal of Radiation Oncology • Biology • Physics. Background Primary...

colorectal cancer

Defensive Beliefs May Prevent Individuals From Partaking in Screening for Colorectal Cancer

Investigators have revealed that individuals who react defensively to an invitation for colorectal cancer screening may be less likely to take part, according to a new study published by Clarke et al in Cancer. Background Colorectal cancer is one of the most treatable cancer types—especially if...

issues in oncology

Researchers Uncover Racial and Ethnic Disparities in Widely Used Precision Oncology Data Registry

Biorepositories created to support precision cancer research through their vast stores of genomic data may lack sufficient representation of cancer distribution among racial and ethnic minorities, according to a new study published by Cheung et al in npj Precision Oncology. The investigators also...

cns cancers

Preclinical Study Shows Losartan May Prevent Immune Checkpoint Inhibitor–Induced Cerebral Edema in Glioblastoma

Researchers revealed that the blood pressure drug losartan may prevent immunotherapy-induced edema and allow patients with glioblastoma to continue receiving immune checkpoint inhibitors without developing adverse effects in the brain, according to a new study published by Datta et al in...

sarcoma
genomics/genetics

ctDNA as a Prognostic Marker in Intermediate-Risk Rhabdomyosarcoma

In a study from the Children’s Oncology Group reported in the Journal of Clinical Oncology, Abbou et al found that measuring circulating tumor DNA (ctDNA) in intermediate-risk rhabdomyosarcoma was feasible and that the presence of ctDNA prior to treatment was associated with poorer prognosis. As...

colorectal cancer
lymphoma
survivorship

Association of Radiation and Procarbazine Dose With Risk of Colorectal Cancer in Survivors of Hodgkin Lymphoma

In a Dutch study reported in JAMA Oncology, Geurts et al found a dose-response relationship between radiotherapy and risk of colorectal cancer among survivors of Hodgkin lymphoma, with the risk being increased with increasing procarbazine dose. Study Details The nested case-control study included...

gynecologic cancers

Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer and High FRα Expression

As reported in the Journal of Clinical Oncology by Ursula A. Matulonis, MD, and colleagues, results from the phase II SORAYA study showed activity of mirvetuximab soravtansine-gynx, an antibody-drug conjugate targeting folate receptor alpha (FRα), in patients with platinum-resistant ovarian cancer...

breast cancer
global cancer care

WHO Launches New Roadmap on Breast Cancer

The World Health Organization (WHO) has released a new Global Breast Cancer Initiative Framework, providing a roadmap to attain targets to save 2.5 million lives from breast cancer by 2040. The new framework recommends that countries implement three pillars of health promotion—early detection,...

Highlights From the 2023 ASCO Gastrointestinal Cancers Symposium

The 2023 ASCO Gastrointestinal Cancers Symposium took place from January 19 to 21 in San Francisco. On this episode, we’re hearing from the presenting authors of three studies reported at that meeting—the SUNLIGHT, SPOTLIGHT, and NAPOLI-3 trials—which examined novel regimens in colorectal, gastric, ...

breast cancer
immunotherapy

FDA Approves Sacituzumab Govitecan-hziy for Pretreated Patients With HR-Positive, HER2-Negative Breast Cancer

On February 3, the U.S. Food and Drug Administration (FDA) approved sacituzumab govitecan-hziy (Trodelvy) for patients with unresectable, locally advanced or metastatic, hormone receptor (HR)-positive, HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, or IHC 2+ with a negative in situ...

breast cancer

Challenges of Accurately Identifying HER2-Low Breast Cancers

The newly identified category of “HER2-low” breast cancer has raised many new issues in this malignancy now that the DESTINY Breast-041 trial determined that fam-trastuzumab deruxtecan-nxki (T-DXd) may effectively treat this tumor. Among the issues are challenges in accurately identifying just...

integrative oncology
symptom management

Massage Therapy May Improve Symptom Burden for Pediatric Patients With Hematologic and/or Oncologic Conditions

A new study from University Hospitals (UH) Connor Whole Health found children, adolescents, and young adults with cancer or sickle cell disease treated at a pediatric academic medical center reported clinically significant reductions in pain, stress, and anxiety in response to massage therapy....

global cancer care

World Cancer Day: Commercial Interests May Drive Millions of Avoidable Cancer Deaths

The Union for International Cancer Control (UICC)—in light of World Cancer Day, taking place on February 4—has called on governments around the world to prioritize policy actions to reduce preventable cancers caused by tobacco use and the consumption of alcohol and ultraprocessed foods, including...

cns cancers

Researchers Develop AI Algorithm to Gain New Insights Into Glioblastoma

Researchers have developed an artificial intelligence (AI) algorithm, known as SPHINKS, capable of performing advanced computational analyses to identify potential therapeutic targets for patients with glioblastoma multiforme. The platform may also have applicability in other cancers, according to...

gynecologic cancers

OCRA Issues Consensus Statement Calling for Consideration of Fallopian Tube Removal to Prevent Ovarian Cancer

The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) has shown that general population screening did not significantly reduce ovarian and tubal cancer deaths, and the researchers concluded that such screening cannot be recommended. The findings from the study prompted the Ovarian Cancer ...

Expert Point of View: Emily K. Curran, MD

Moderator of the session, Emily K. Curran, MD, Assistant Professor of Internal Medicine at the University of Cincinnati Cancer Center, in Ohio, said that the data presented by Dr. Short and colleagues demonstrated very impressive event-free and overall survival rates, especially for a disease that...

leukemia

Ponatinib and Blinatumomab Combination Safe and Effective in Patients With Newly Diagnosed, Ph-Positive ALL

The combination of ponatinib and blinatumomab has led to rapid and durable remissions in patients with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), according to data presented at the 2022 American Society of Hematology (ASH) Annual Meeting and...

issues in oncology

Review Provides Recommendations on Cancer Treatment in the Context of Preexisting Dementia

According to a review published by Ashley et al in CA: A Cancer Journal for Clinicians, preexisting dementia may complicate cancer care and increase the risk of worse clinical outcome and inferior patient experience. People living with dementia are more likely to have cancer diagnosed at an...

colorectal cancer

Neoadjuvant Plus Adjuvant Chemotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Colon Cancer

As reported in the Journal of Clinical Oncology by Morton et al, the European phase III FOxTROT trial has shown that neoadjuvant plus adjuvant oxaliplatin/fluoropyrimidine resulted in a reduced risk of residual disease or disease recurrence vs adjuvant oxaliplatin/fluoropyrimidine in patients with...

lung cancer

Surgical Quality Metric Scoring and Survival Among U.S. Veterans With Early-Stage NSCLC

In a study reported in JAMA Surgery, Heiden et al developed a surgical quality metric scoring system—the Veterans Affairs Lung Cancer Operative quality (VALCAN-O) score—that was associated with overall survival in U.S. veterans undergoing curative-intent surgery for early-stage non–small cell lung...

issues in oncology

Consuming Ultraprocessed Foods May Be Linked to Increased Cancer Risk and Mortality

Higher consumption of ultraprocessed foods may be linked to increased cancer burden and mortality, according to a new, UK-based study published by Chang et al in eClinicalMedicine. Ultraprocessed foods are food items which have been heavily processed during their production—such as fizzy drinks,...

lung cancer
genomics/genetics

Adjuvant Osimertinib May Significantly Improve Disease-Free Survival for Patients With Resected EGFR-Mutant NSCLC

The EGFR tyrosine kinase inhibitor osimertinib may improve rates of disease-free survival and reduce the risk of recurrence in patients with resected, EGFR­-mutant non–small cell lung cancer (NSCLC), according to a new exploratory analysis of the ADAURA trial published by Roy S. Herbst, MD, PhD,...

sarcoma

Addition of Anti–IGF-1R Antibody Ganitumab to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Metastatic Ewing Sarcoma

As reported in the Journal of Clinical Oncology by DuBois et al, the Children’s Oncology Group phase III AEWS1221 trial showed no event-free survival benefit with the addition of the anti–insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody ganitumab to interval-compressed...

survivorship
leukemia
lymphoma
sarcoma

Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer Treated With Doxorubicin

In a study reported in the Journal of Clinical Oncology, Eric J. Chow, MD, MPH, and colleagues found that the use of dexrazoxane was associated with long-term protection of heart function in childhood cancer survivors who received doxorubicin for their cancer. According to the study investigators,...

cns cancers
survivorship

Canadian Trial Highlights Adverse Outcomes in Survivors of Childhood Medulloblastoma

In a population-based study reported in the Journal of Clinical Oncology, Coltin et al found that survivors of childhood medulloblastoma in Ontario were at an increased risk of numerous adverse health outcomes compared with matched noncancer controls.  Study Details In the study, all 5-year...

colorectal cancer

Levels of Inflammatory Biomarkers and Survival in Patients Receiving Adjuvant Therapy for Stage III Colon Cancer

In a study reported in JAMA Oncology, Cheng et al found that higher levels of inflammatory biomarkers measured after surgery—but before receipt of chemotherapy—were associated with poorer outcomes in patients with stage III colon cancer enrolled in the CALGB/SWOG 80702 trial of adjuvant...

breast cancer

Study Finds Breast MRI Superior vs Other Supplementary Screening Tests for Detecting Breast Cancer in Patients With Dense Breasts

Compared to other common supplemental screening methods, breast magnetic resonance imaging (MRI) was superior at detecting breast cancer in patients with dense breasts, according to a new study published by Hussein et al in Radiology. Background Breast cancer is one of the leading causes of cancer...

breast cancer

Gap Discovered in Breast Cancer Radiotherapy Recommendations for Patients Aged 70 vs 69 Years

Age-based heuristics may lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new study published by Talcott et al in the International Journal of Radiation Oncology, Biology, and Physics. Background Radiation therapy often is given...

sarcoma
solid tumors
lymphoma

MDM2 Inhibitor Milademetan in Advanced Liposarcoma, Solid Tumors, or Lymphomas

In a first-in-human, phase I, dose-escalation and dose-expansion study reported in the Journal of Clinical Oncology, Mrinal M. Gounder, MD, and colleagues identified the dose and schedule for further evaluation of the oral MDM2 inhibitor milademetan in a population of patients with advanced...

pancreatic cancer

Zev A. Wainberg, MD, on Pancreatic Ductal Adenocarcinoma: Recent Findings on NALIRIFOX vs Nab-paclitaxel Plus Gemcitabine

Zev A. Wainberg, MD, of the UCLA School of Medicine, discusses phase III findings from the NAPOLI-3 trial, which showed that first-line NALIRIFOX (liposomal irinotecan plus fluorouracil/leucovorin plus oxaliplatin) improved overall and progression-free survival compared with nab-paclitaxel plus...

breast cancer

Association of PRS313 Polygenic Risk Score With Tumor Characteristics and Survival in Patients With Invasive Breast Cancer

In a study reported in the Journal of Clinical Oncology, Josephine M.N. Lopes Cardozo, MD, PhD, and colleagues found that a higher score on a polygenic risk score consisting of 313 common genetic variants (the PRS313) was generally associated with more favorable tumor characteristics in patients...

lung cancer
immunotherapy

Uptake of Immune Checkpoint Inhibitors and Survival Among Younger and Older Patients With Advanced NSCLC

In a U.S. cohort study reported in JAMA Oncology, Voruganti et al found that the uptake of immune checkpoint inhibitor therapy for patients with advanced non–small cell lung cancer (NSCLC) has been associated with “modest” improvements in overall survival, particularly among older patients. As...

global cancer care

Sex Disparities in Childhood Cancer Diagnoses in India

In a study reported in The Lancet Oncology, Bhatia et al found that boys were significantly more likely than girls to be diagnosed with childhood cancers in India. Study Details The retrospective multicohort study involved individual data from patients aged 0 to 19 years from hospital-based records ...

thyroid cancer

Genomic Screening May Help Detect Medullary Thyroid Cancer, Study Finds

Population-based genomic screening may facilitate early detection of medullary thyroid cancer in patients with variants in the RET gene, according to a new study published by Pichardo et al in JAMA Otolaryngology–Head & Neck Surgery. Background Medullary thyroid cancer accounts for 2% to 5% of...

hematologic malignancies

Momelotinib May Effectively Reduce Anemia and Other Symptoms for Patients With Myelofibrosis

The targeted therapy momelotinib may offer clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, for patients with myelofibrosis, according to a novel study published by Srdan Verstovsek, MD, PhD, and colleagues in The Lancet. The findings support...

breast cancer

Association of Immune-Related Gene Expression Signatures and TILs With Outcomes in Early-Stage HER2-Positive Breast Cancer

In a study reported in JAMA Oncology, Aranzazu Fernandez-Martinez, MD, PhD, and colleagues found that several B-cell–related gene signatures provided better prediction of pathologic complete response and event-free survival than tumor-infiltrating lymphocyte (TIL) levels among patients with...

colorectal cancer
immunotherapy

Immunotherapy Combined With Targeted Therapy in Patients With BRAF V600E–Mutated Colorectal Cancer

In one of the first clinical trials combining immunotherapy and targeted therapy for patients with BRAF V600E–mutated colorectal cancer, researchers discovered that a combination regimen of dabrafenib, trametinib, and spartalizumab resulted in long-lasting responses. The study findings published by ...

hepatobiliary cancer

Laura A. Dawson, MD, on Hepatocellular Carcinoma: Phase III Data on Sorafenib vs Stereotactic Body Radiation Therapy

Laura A. Dawson, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings from the NRG/RTOG1112 study, which showed that stereotactic body radiation therapy (SBRT) administered prior to sorafenib vs sorafenib alone, improved outcomes in patients with advanced hepatocellular...

gastroesophageal cancer
gastrointestinal cancer

Kohei Shitara, MD, on Gastric or Gastroesophageal Junction Adenocarcinoma: Recent Data on Zolbetuximab Plus mFOLFOX6

Kohei Shitara, MD, of Japan’s National Cancer Center Hospital East, discusses the SPOTLIGHT study’s phase III findings on zolbetuximab plus mFOLFOX6 as first-line treatment for patients with the biomarker claudin-18.2–positive and HER2-negative locally advanced unresectable or metastatic gastric or ...

breast cancer

Two Methods Studied in Defining Prognosis for Patients With ER-Positive, Node-Positive Breast Cancer

In a study reported in the Journal of Clinical Oncology, Corey W. Speers, MD, PhD, and colleagues found that the sensitivity to endocrine therapy (SET2,3) index and the 21-gene breast recurrence score (RS) were not correlated in defining prognosis among postmenopausal patients with estrogen...

hepatobiliary cancer

Adjuvant S-1 vs Observation for Resected Biliary Tract Cancer

In a Japanese phase III trial (JCOG1202, ASCOT) reported in The Lancet, Nakachi et al found that adjuvant S-1 was associated with significantly improved overall survival vs observation in patients with resected biliary tract cancer. Study Details The multicenter, open-label trial included 440...

hepatobiliary cancer

Adjuvant FOLFOX Hepatic Arterial Infusion in Hepatocellular Carcinoma With Microvascular Invasion

In a Chinese phase III trial reported in the Journal of Clinical Oncology, Li et al found that adjuvant hepatic arterial infusion chemotherapy with FOLFOX (fluorouracil, leucovorin, and oxaliplatin) significantly improved disease-free survival vs routine follow-up in patients with hepatocellular...

lymphoma

FDA Grants Accelerated Approval to Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

On January 27, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib (Jaypirca) for patients with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BRUIN Efficacy was...

breast cancer

FDA Approves Elacestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

On January 27, the U.S. Food and Drug Administration (FDA) approved elacestrant (Orserdu) for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine...

gastrointestinal cancer

Souya Nunobe, MD, PhD, on Gastric Cancer: 5-Year Follow-up on S-1 Chemotherapy for Stage II Disease

Souya Nunobe, MD, PhD, of Japan’s Cancer Institute Hospital and the Japanese Foundation for Cancer Research, discusses 5-year follow-up results of the phase III OPAS-1 trial, which compared four and eight courses of S-1, a novel oral fluoropyrimidine derivative adjuvant chemotherapy for patients...

Advertisement

Advertisement



Advertisement